Penumbra Inc
$ 329.77
0.08%
10 Apr - close price
- Market Cap 12,941,181,000 USD
- Current Price $ 329.77
- High / Low $ 330.11 / 328.97
- Stock P/E 72.96
- Book Value 36.39
- EPS 4.52
- Next Earning Report 2026-04-22
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.14 %
- 52 Week High 362.41
- 52 Week Low 221.26
About
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
Analyst Target Price
$365.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-07-29 | 2025-05-05 | 2025-02-20 | 2024-10-30 | 2024-07-30 | 2024-05-07 | 2024-02-22 | 2023-11-02 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 1.18 | 0.97 | 0.86 | 0.83 | 0.97 | 0.85 | 0.64 | 0.41 | 0.76 | 0.67 | 0.43 | 0.23 |
| Estimated EPS | 1.1 | 0.9265 | 0.83 | 0.7547 | 0.8937 | 0.69 | 0.56 | 0.38 | 0.7 | 0.45 | 0.28 | 0.11 |
| Surprise | 0.08 | 0.0435 | 0.03 | 0.0753 | 0.0763 | 0.16 | 0.08 | 0.03 | 0.06 | 0.22 | 0.15 | 0.12 |
| Surprise Percentage | 7.2727% | 4.6951% | 3.6145% | 9.9775% | 8.5375% | 23.1884% | 14.2857% | 7.8947% | 8.5714% | 48.8889% | 53.5714% | 109.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-22 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PEN
2026-04-08 06:09:29
Kahn Swick & Foti, LLC is investigating the proposed sale of medical device company Penumbra, Inc. to Boston Scientific Corporation. The law firm aims to determine if the consideration of $374 in cash or 3.8721 shares of Boston Scientific stock per Penumbra share and the sale process are adequate or if the price undervalues Penumbra. This investigation highlights the importance of ensuring fair value for shareholders in merger and acquisition deals within the medical device industry.
2026-04-08 02:41:07
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). The law firm is seeking to determine if the proposed consideration of $374.00 per share in cash or 3.8721 shares of Boston Scientific stock adequately values Penumbra. Shareholders who believe the Company is undervalued are encouraged to contact KSF to discuss their legal rights.
2026-04-08 02:09:29
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). The law firm is scrutinizing whether the proposed consideration of $374.00 in cash or 3.8721 shares of Boston Scientific stock adequately values Penumbra for its shareholders. KSF encourages Penumbra shareholders who believe the offer undervalues the company to contact them for legal consultation.
2026-04-07 03:40:07
Penumbra (NYSE:PEN) reported the strongest Q4 results within the medical devices and supplies industry for cardiology, neurology, and vascular care, with revenues of $385.4 million, up 22.1% year-on-year, significantly beating analyst estimates. While the sector generally showed strong Q4 revenues, stock prices for these companies have declined. Merit Medical Systems (MMSI) also had a strong quarter, whereas Artivion (AORT) and ICU Medical (ICUI) experienced slower performance or stock declines despite some positive beats.
2026-04-07 02:11:08
Penumbra (NYSE:PEN) Director Harpreet Grewal sold 100 shares of the company's stock on April 2nd for $32,822.00, reducing his stake by 1.13% to 8,719 shares. This transaction follows a previous sale in January. The company recently missed quarterly EPS estimates but exceeded revenue expectations, and analysts currently rate the stock as "Hold."
2026-04-07 00:11:08
Penumbra Inc. director Harpreet Grewal sold 100 shares of common stock at $328.22 per share on April 2, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction leaves Grewal with 8,719 shares directly held, with a portion of these still subject to vesting conditions. The sale was an open-market transaction and is considered neutral in its filing impact but negative in sentiment.
